Key result
Pre-treatment breast, lung, and colorectal cancers increased atrial fibrillation prevalence vs controls via KRT16-EndMT.
Why the study?
Anticancer therapy increases the incidence of AF, but whether multiple cancers directly promote AF independently of anticancer therapy through shared mechanisms remained unclear.
Does tumor-derived circulating KRT16 promote atrial remodeling and atrial fibrillation via endothelial-to-mesenchymal transition in female patients with untreated breast, lung, or colorectal cancer and in tumor-bearing mouse models?
Cohort (n=5,612)
No
Does tumor-derived circulating KRT16 promote atrial remodeling and atrial fibrillation via endothelial-to-mesenchymal transition in female patients with untreated breast, lung, or colorectal cancer and in tumor-bearing mouse models?
Multiple untreated cancers directly increase atrial fibrillation prevalence in patients and drive atrial fibrosis and arrhythmia inducibility in mice via tumor-secreted KRT16 binding to endothelial AnxA2 to activate TGF-β1-mediated endothelial-to-mesenchymal transition.
Answers are grounded in this paper and cite their sources.
Pre-treatment cancers may warrant AF screening in women; leaves open causal role of KRT16-EndMT in prospective studies.
Anticancer therapy increases the incidence of atrial fibrillation (AF), the most common sustained cardiac arrhythmia worldwide. However, whether multiple cancers directly promote AF independently of anticancer therapy through shared mechanisms remains unclear. Here, retrospective clinical analyses revealed significantly increased AF prevalence in pre-treatment female patients with breast cancer (BC), lung cancer (LC), and colorectal cancer (CRC), independent of anticancer therapy. Consistently, orthotopic tumor-bearing mouse models exhibited enhanced AF inducibility accompanied by atrial enlargement, fibrosis, and electrical remodeling. Integrated transcriptomic analyses, combined with the TCGA datasets, identified endothelial-to-mesenchymal transition (EndMT) as a shared atrial remodeling pathway underlying tumor-associated AF across multiple cancers. Mechanistically, keratin 16 (KRT16) acted as a shared circulating factor across multiple malignancies. KRT16 accumulated in atrial endothelial cells and promoted EndMT through annexin A2 (AnxA2)-dependent activation of TGF-β1/Smad signaling. KRT16 promoted abnormal membrane retention of AnxA2 by suppressing Tyr23 phosphorylation, thereby sustaining profibrotic signaling and atrial remodeling. Genetic silencing of KRT16 in cancer cells or endothelial knockdown of AnxA2 markedly attenuated EndMT, atrial fibrosis, and AF susceptibility in tumor-bearing mice. Our findings demonstrate that multiple cancers directly induce atrial remodeling and AF through a shared mechanism centered on KRT16-driven EndMT, identifying this pathway as a potential therapeutic target.
No takes yet. Share an insight, caveat, or question.
Zhan et al. (2026) conducted a cohort in Pre-treatment breast cancer, lung cancer, or colorectal cancer and atrial fibrillation (n=5,612). Pre-treatment breast, lung, or colorectal cancer (and circulating tumor-derived KRT16) vs. Healthy female controls without malignant cancer history (n = 3,205) was evaluated on Prevalence of atrial fibrillation (AF) detected by dynamic ECG / Holter prior to anticancer therapy (primary clinical comparison: pre-treatment breast cancer vs healthy controls) (OR 7.47, 95% CI 4.77-11.70, p=<0.001). Pre-treatment breast, lung, and colorectal cancers increased atrial fibrillation prevalence vs controls via KRT16-EndMT.
Synapse has enriched 10 related papers. Consider them for comparative context: